secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001193125-24-211548
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 1.02, 2.03, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions closes $250M term loan with Oak Hill Advisors; extends maturity to 2029
--------------------------------------------------------------------------------

- $250M term loan drawn in full, matures August 2029; used to repay existing senior term loan due May 2025 and terminate revolver.
- Issued warrants for 2.5M shares at 110% and 175% of 30-day VWAP; agreed to issue $10M in common stock at VWAP.
- Interest at SOFR+8.25% or Base Rate+7.25%; default rate +2%; covenants include $75M minimum liquidity and leverage ratio tests.
- New facility expected to reduce net debt by >$200M in 2024; management cites greater operational flexibility for turnaround.
- Oak Hill Advisors serves as lead agent; company to participate in Wells Fargo and H.C. Wainwright conferences in September.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000119312524211548/0001193125-24-211548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000119312524211548/d873622d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-211548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer